MXPA04003866A - Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. - Google Patents

Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.

Info

Publication number
MXPA04003866A
MXPA04003866A MXPA04003866A MXPA04003866A MXPA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A
Authority
MX
Mexico
Prior art keywords
agonist
estrogen
treating unstable
overactive bladder
muscarinic agent
Prior art date
Application number
MXPA04003866A
Other languages
English (en)
Spanish (es)
Inventor
Versi Ebrahim
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MXPA04003866A publication Critical patent/MXPA04003866A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA04003866A 2001-11-09 2002-11-07 Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. MXPA04003866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34450701P 2001-11-09 2001-11-09
PCT/SE2002/002041 WO2003039524A1 (en) 2001-11-09 2002-11-07 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder

Publications (1)

Publication Number Publication Date
MXPA04003866A true MXPA04003866A (es) 2004-07-08

Family

ID=23350815

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04003866A MXPA04003866A (es) 2001-11-09 2002-11-07 Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
MXPA04004364A MXPA04004364A (es) 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA04004364A MXPA04004364A (es) 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.

Country Status (6)

Country Link
US (2) US20030118633A1 (enExample)
EP (2) EP1441707A1 (enExample)
JP (2) JP2005512995A (enExample)
CA (2) CA2466336A1 (enExample)
MX (2) MXPA04003866A (enExample)
WO (2) WO2003039524A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226972B2 (en) 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
WO2004043429A1 (en) * 2002-11-12 2004-05-27 Pharmacia & Upjohn Company Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, and at least one agent selected from an estrogen and an anti-muscarinic
MXPA05007266A (es) 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1792629A4 (en) * 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US8217024B2 (en) * 2005-12-27 2012-07-10 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US7825107B2 (en) 2006-05-22 2010-11-02 Hormos Medical Ltd. Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors
KR20090029237A (ko) 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
WO2008148013A1 (en) 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
JP2011518783A (ja) * 2008-04-09 2011-06-30 コンサート ファーマシューティカルズ インコーポレイテッド ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法
JP5608160B2 (ja) 2008-04-17 2014-10-15 ミセル テクノロジーズ、インコーポレイテッド 生体吸収性の層を有するステント
GR1006406B (el) * 2008-05-06 2009-05-26 Specifar Abee ���������� ������� ��� ������������� ��������� Μικροδισκια παρατεταμενης αποδεσμευσης της τρυγικης τολτεροδινης
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2687215B1 (en) * 2012-07-18 2018-11-28 Georges Debled Mesterolone pharmaceutical composition for dihydrotestosterone deficiencies in woman
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
BR112016009008B8 (pt) * 2013-10-22 2023-01-31 Therapeuticsmd Inc Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol
WO2018093369A1 (en) * 2016-11-17 2018-05-24 Goren Ofer A Treatment of sexual dysfunction and for improved sexual quality of life
JP2024531662A (ja) * 2021-09-10 2024-08-29 スタテラ ファーマ インコーポレイティド 腹圧性尿失禁及び便失禁の治療、軽減及び／又は予防のための成長及び修復促進化合物の局所送達

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262115A (en) * 1882-08-01 Moeeis pollak
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
CA2259012C (en) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
CZ302630B6 (cs) * 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
KR20020011437A (ko) * 1999-06-11 2002-02-08 추후보정 여성에 비-경구 안드로겐형 스테로이드의 투여
EA006154B1 (ru) * 2001-03-28 2005-10-27 Пфайзер Инк. N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad

Also Published As

Publication number Publication date
WO2003039524A1 (en) 2003-05-15
MXPA04004364A (es) 2004-08-11
US20030118633A1 (en) 2003-06-26
WO2003039553A1 (en) 2003-05-15
EP1441707A1 (en) 2004-08-04
CA2466336A1 (en) 2003-05-15
JP2005512995A (ja) 2005-05-12
EP1443939A1 (en) 2004-08-11
WO2003039553B1 (en) 2004-07-08
JP2005514345A (ja) 2005-05-19
US20030130244A1 (en) 2003-07-10
CA2464707A1 (en) 2003-05-09

Similar Documents

Publication Publication Date Title
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20043354B (en) Therapeutic Formulation for Administering Tolterodine with Controlled Release
CA2427227A1 (en) Lactam compound
CA2376916A1 (en) Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
EP1933833B8 (en) Therapy for the treatment of overactive bladder
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
AU2003240113B2 (en) Formulation of nefopam and its use in the treatment of pain
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
WO2003015690B1 (en) Method for treating primary insomnia
AP1896A (en) The method of treating cancer
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
WO2001068076A8 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
SE0102887D0 (sv) New formulation
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
MY133438A (en) Morpholinobenzamide salts

Legal Events

Date Code Title Description
FA Abandonment or withdrawal